Page 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 1934 FORM 10 - K TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF For the fiscal year ended June 30 , 2021 DELAWARE ( State or other jurisdiction of incorporation or organization ) OR For the transition period from Title of each class Common Stock , $ 0.00000002 par value Commission File Number : 000-50484 MEI Pharma , Inc. ( Exact name of registrant as specified in its charter ) to 11455 El Camino Real , San Diego , CA 92130 ( Address of principal executive offices ) ( Zip Code ) ( 858 ) 369-7100 ( Registrant's telephone number , including area code ) Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol MEIP None ( Title of Class ) ( I.R.S. Employer Identification No. ) Securities registered pursuant to Section 12 ( g ) of the Act : 51-0407811 Name of each exchange on which registered The NASDAQ Stock Market LLC Indicate by a check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes Indicate by a check mark if the registrant not required to file reports pursuant to Section 13 or Section 15 ( d ) the Act . 0 No X No X